|
Cholestasis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury.
|
20974703 |
2011 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury.
|
20974703 |
2011 |
|
Peliosis Hepatis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury.
|
20974703 |
2011 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury.
|
20974703 |
2011 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury.
|
20974703 |
2011 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury.
|
20974703 |
2011 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury.
|
20974703 |
2011 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury.
|
20974703 |
2011 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Par-4 activity and levels can be downregulated in several tumors and cancer cell types, indicating poor prognosis and treatment resistance.
|
30474528 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, IKM5 amplified the expression and nuclear translocation of tumor suppressor Par-4 to control NF-kB-mediated pro-EMT activities.
|
31175498 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Par-4 activity and levels can be downregulated in several tumors and cancer cell types, indicating poor prognosis and treatment resistance.
|
30474528 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Par-4 induces apoptosis selectively in various types of cancer cells but not normal cells.
|
29695515 |
2018 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Previous study revealed that the expression of PAR4 was increased in colorectal cancer tissues compared with the associated normal tissues, particularly in positive lymph node and poorly differentiated types of cancer.
|
30333860 |
2018 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Par-4 down-regulation is often observed in cancer while up-regulation is characteristic of neurodegenerative conditions such as Alzheimer's disease.
|
30518159 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we explored the relationship between PAR4 activation and the expression of p16, and elucidated the underlying mechanisms in PAR4 inducing the tumor suppressor role in ESCC.
|
30363984 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using an epigenome editing approach to reexpress Par-4 by specifically reversing the histone modifications found in recurrent tumors, we found that Par-4 reexpression sensitized recurrent tumors to chemotherapy in vitro and in vivo.
|
30148456 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these results indicate that residual breast cancer tumor cell survival and recurrence requires circumventing Foxo-driven Par-4 upregulation and suggest that approaches to enforce Par-4 expression may prevent residual cell survival and recurrence.<i></i>.
|
29330285 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Par-4 down-regulation is often observed in cancer while up-regulation is characteristic of neurodegenerative conditions such as Alzheimer's disease.
|
30518159 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Par-4 induces apoptosis selectively in various types of cancer cells but not normal cells.
|
29695515 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Previous study revealed that the expression of PAR4 was increased in colorectal cancer tissues compared with the associated normal tissues, particularly in positive lymph node and poorly differentiated types of cancer.
|
30333860 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transcripts for genes (<i>F2RL3, EMILIN1</i> and <i>CDC42BPA</i>) previously identified as being differentially methylated or expressed in smoking or smoking-related cancers were overexpressed in smokers compared to non-smokers and the expression of transcripts for genes (<i>HERPUD1, GAB2, FAM167A</i> and <i>GLS</i>) previously associated with stress response, autoimmune disease and cancer were associated with telomere length.
|
29207374 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We report that the anti-malarial drug, chloroquine (CQ), is a robust inducer of Par-4 secretion from normal cells in mice and cancer patients in a clinical trial.
|
28076793 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For instance, we demonstrate using ChIP-seq analysis that estrogen downregulate tumor suppressor Par-4 in hormone-dependent cells by directly binding to its DNA regulatory elements and inhibiting estrogen signaling could reinstate Par-4 apoptosis-inducing abilities.
|
28008141 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer-associated fibroblasts promote cancer cell growth through a miR-7-RASSF2-PAR-4 axis in the tumor microenvironment.
|
27901488 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chloroquine-Inducible Par-4 Secretion Is Essential for Tumor Cell Apoptosis and Inhibition of Metastasis.
|
28076793 |
2017 |